Drug intelligence / Profile preview

macrogol 4000

Development stage: Phase 4
Modality: Small Molecules
Administration: Oral

Overview

Macrogol 4000 is an osmotic laxative used for the symptomatic treatment of constipation in adults and children. It works by binding water molecules in the intestinal tract through hydrogen bonds, increasing stool volume and softening its consistency to relieve constipation. The medication is not absorbed into the bloodstream to any significant extent and is not broken down in the body. Effects typically become apparent within 24-48 hours of administration.

Brand names: macrogol 4000macrogol4000macrogol-4000Forlax
Other names: Polyethylene glycol 4000PEG 4000PEG4000PEG-4000

Beyond the preview

Go deeper on macrogol 4000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on macrogol 4000.

Explore the full profile